R. Harvey III
Academic Appointment
- Professor, Department of Pharmacology, Emory University School of Medicine
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- PharmD from University of North Carolina at Chapel Hill, Chapel Hill
- BS from University of North Carolina at Chapel Hill, Chapel Hill
Research
Focus
- My research focuses on the application of clinical pharmacology principles to improved cancer treatment outcomes in phase 1 trials. Individualized care through clinical, pharmacokinetic (PK), and pharmacodynamic (PD) endpoint measurement in general and unique populations (e.g., renal, hepatic dysfunction) drives the work we do in our clinical trials program.
Publications
-
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Cancer Chemother Pharmacol Volume: 95 Page(s): 24
01/17/2025 Authors: Maher KR; Shafer D; Schaar D; Bandyopadhyay D; Deng X; Wright J; Piekarz R; Rudek MA; Harvey RD; Grant S -
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement.
J Clin Oncol Volume: 42 Page(s): 3986 - 3995
11/20/2024 Authors: Thota R; Hurley PA; Miller TM; Bruinooge SS; Lipset C; Harvey RD; Black LJ; Dinsdale A; Merrill JK; Pollastro T -
Bisbiguanide analogs induce mitochondrial stress to inhibit lung cancer cell invasion.
iScience Volume: 27 Page(s): 109591
04/19/2024 Authors: Knippler CM; Arnst JL; Robinson IE; Matsuk V; Khatib TO; Harvey RD; Shanmugam M; Mouw JK; Fu H; Ganesh T -
A call to action to advance patient-focused and decentralized clinical trials.
Cancer Volume: 130 Page(s): 1193 - 1203
04/15/2024 Authors: Harvey RD; Miller TM; Hurley PA; Thota R; Black LJ; Bruinooge SS; Boehmer LM; Fleury ME; Kamboj J; Rizvi MA -
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Cancer Med Volume: 13
03/01/2024 Authors: Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jaez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ -
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Clin Ther Volume: 46 Page(s): 228 - 238
03/01/2024 Authors: Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T -
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Clin Cancer Res Volume: 30 Page(s): 522 - 531
02/01/2024 Authors: Carneiro BA; Cavalcante L; Mahalingam D; Saeed A; Safran H; Ma WW; Coveler AL; Powell S; Bastos B; Davis E -
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Oncologist Volume: 28 Page(s): 1055 - 1063
12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H -
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Haematologica Volume: 108 Page(s): 3460 - 3463
12/01/2023 Authors: Lee JS; Wagner CB; Prelewicz S; Kurish HP; Walchack R; Cenin DA; Patel S; Lo M; Schlafer D; Li BKT -
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
JCO Oncol Pract Volume: 19 Page(s): 793 - 798
09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK -
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Volume: 70 Page(s): e30405
08/01/2023 Authors: Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC -
Debunking Sex and Disentangling Gender From Oncology.
J Clin Oncol Volume: 41 Page(s): 3791 - 3795
08/01/2023 Authors: Alpert AB; Rivers L; Manzano C; Ruddick R; Adams S; Obedin-Maliver J; Harvey RD; Griggs JJ; Operario D -
The earlier the better? Or better late than never? Dose optimization in oncology.
J Natl Cancer Inst Volume: 115 Page(s): 485 - 487
05/08/2023 Authors: Harvey RD -
IMPLICATIONS OF RACE FREE RENAL FUNCTION EQUATIONS ON BLACK PATIENTS WITH RENAL CELL CARCINOMA
Volume: 209 Page(s): E133 - E134
04/01/2023 Authors: Schmeusser BN; Palacios AR; Midenberg E; Nabavizadeh R; Ali A; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K -
Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment.
Cancer Volume: 129 Page(s): 920 - 924
03/15/2023 Authors: Schmeusser BN; Palacios AR; Midenberg ER; Nabavizadeh R; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K; Bilen MA -
Effect of race-free estimated glomerular filtration rate equations (eGFR) on oncology clinical trial eligibility for Black patients.
Volume: 41
02/20/2023 Authors: Schmeusser B; Palacios AR; Midenberg E; Nabavizadeh R; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K; Bilen MA -
Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback.
BMC Med Ethics Volume: 24 Page(s): 12
02/19/2023 Authors: Avinger AM; Sibold HC; Campbell G; Abernethy E; Bourgeois J; McClary T; Blee S; Dixon M; Harvey RD; Pentz RD -
Chemotherapy dosing in older adults with cancer: One size does NOT fit all.
J Geriatr Oncol Volume: 14 Page(s): 101363
01/01/2023 Authors: Williams GR; Outlaw D; Harvey RD; Lichtman SM; Zamboni WC; Giri S -
Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer.
JCO Oncol Pract Volume: 18 Page(s): e1807 - e1817
11/01/2022 Authors: Jimenez RB; Schenkel C; Levit LA; Hu B; Lei XJ; Harvey RD; Morrison VA; Pollastro T; Waterhouse D; Weekes C -
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs Volume: 40 Page(s): 1042 - 1050
10/01/2022 Authors: Zhou X; Vaishampayan U; Mahalingam D; Harvey RD; Chung KY; Sedarati F; Dong C; Faller DV; Venkatakrishnan K; Gupta N -
Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.
Cancer Invest Volume: 40 Page(s): 654 - 662
08/01/2022 Authors: Papautsky EL; Carlson M; Johnson SM; Montague H; Valero L; Attai DJ; Harvey RD; Lyman GH; Lustberg M -
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
Ann Pharmacother Volume: 56 Page(s): 927 - 940
08/01/2022 Authors: Arnall JR; Maples KT; Harvey RD; Moore DC -
Improving First in Human and Window of Opportunity Informed Consent Forms Through Participant Feedback
Volume: 17 Page(s): 405 - 406
07/01/2022 Authors: Sibold HC; Campbell G; Abernethy E; Bourgeois J; Dixon M; Harvey RD; Pentz RD -
Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity.
JAMA Oncol Volume: 8 Page(s): 821 - 822
06/01/2022 Authors: Goldstein DA; Harvey RD; Chan KKW -
A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain.
Pharmacotherapy Volume: 42 Page(s): 298 - 310
04/01/2022 Authors: Singh V; Gillespie TW; Lane O; Spektor B; Zarrabi AJ; Egan K; Curseen K; Tsvetkova M; Beumer JH; Sniecinski R -
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective.
J Adv Pract Oncol Volume: 13 Page(s): 198 - 201
04/01/2022 Authors: Harvey RD; Begue A; Raine C; Yabroff R -
Call to Action for Improving Oral Anticancer Agent Adherence.
J Clin Oncol Volume: 40 Page(s): 1036 - 1040
04/01/2022 Authors: Levit LA; Arora S; Kluetz PG; Magnuson A; Rahman A; Harvey RD -
Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis
Volume: 33 Page(s): S12 - S12
03/08/2022 Authors: Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM -
SETTING THE STANDARD FOR INVESTIGATIONAL DRUG ADMINISTRATION
Volume: 49 Page(s): E16 - E16
03/01/2022 Authors: Clark D; Garcia C; Bourgeois J; Rogers S; Park E; Harvey D -
Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding?
Ethics Hum Res Volume: 44 Page(s): 18 - 25
03/01/2022 Authors: Campbell G; Dixon MD; Lohani M; Cook J; Hianik R; Thomson MC; Abernethy E; Lewis C; Switchenko J; Harvey RD -
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Pharmacotherapy Volume: 42 Page(s): 233 - 240
03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK -
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Lancet Oncol Volume: 22 Page(s): 1777 - 1786
12/01/2021 Authors: Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM -
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity.
Expert Rev Anticancer Ther Volume: 21 Page(s): 1145 - 1159
10/01/2021 Authors: Shayne M; Harvey RD; Lyman GH -
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Invest New Drugs Volume: 39 Page(s): 1057 - 1071
08/01/2021 Authors: Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM -
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Ann Pharmacother Volume: 55 Page(s): 921 - 931
07/01/2021 Authors: Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND -
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
J Clin Oncol Volume: 39 Page(s): 2037 - 2048
06/20/2021 Authors: Griggs JJ; Bohlke K; Balaban EP; Dignam JJ; Hall ET; Harvey RD; Hecht DP; Klute KA; Morrison VA; Pini TM -
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies.
Am Soc Clin Oncol Educ Book Volume: 41 Page(s): e286 - e293
06/01/2021 Authors: Carlisle JW; Harvey RD -
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care.
J Oncol Pharm Pract Volume: 27 Page(s): 785 - 801
06/01/2021 Authors: Holle LM; Bilse T; Alabelewe RM; Kintzel PE; Kandemir EA; Tan CJ; Weru I; Chambers CR; Dobish R; Handel E -
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.
Clin Cancer Res Volume: 27 Page(s): 2394 - 2399
05/01/2021 Authors: Kim ES; Uldrick TS; Schenkel C; Bruinooge SS; Harvey RD; Magnuson A; Spira A; Wade JL; Stewart MD; Vega DM -
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.
Clin Cancer Res Volume: 27 Page(s): 2400 - 2407
05/01/2021 Authors: Harvey RD; Mileham KF; Bhatnagar V; Brewer JR; Rahman A; Moravek C; Kennedy AS; Ness EA; Dees EC; Ivy SP -
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
Clin Cancer Res Volume: 27 Page(s): 2430 - 2434
05/01/2021 Authors: Harvey RD; Bruinooge SS; Chen L; Garrett-Mayer E; Rhodes W; Stepanski E; Uldrick TS; Ison G; Khozin S; Rubinstein WS -
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Clin Cancer Res Volume: 27 Page(s): 916 - 921
02/15/2021 Authors: Kluetz PG; Keegan P; Demetri GD; Thornton K; Sul J; Kim J; Katzen H; Burke LB; Harvey RD; Alebachew E -
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Front Oncol Volume: 11 Page(s): 786120
01/01/2021 Authors: Gordon MS; Shapiro GI; Sarantopoulos J; Juric D; Lu B; Zarotiadou A; Connarn JN; Le Bruchec Y; Dumitru CD; Harvey RD -
Current developments in the combination therapy of relapsed/refractory multiple myeloma.
Expert Rev Anticancer Ther Volume: 20 Page(s): 1021 - 1035
12/01/2020 Authors: Maples KT; Joseph NS; Harvey RD -
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT -
PRELIMINARY SAFETY, PHARMACOKINETICS/PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
Volume: 8 Page(s): A247 - A248
11/01/2020 Authors: Shum E; Daud A; Reilley M; Najjar Y; Thompson J; Baranda J; Harvey RD; Leidner R; Shields A; Cohen E -
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Clin Cancer Res Volume: 26 Page(s): 5329 - 5337
10/15/2020 Authors: Connolly RM; Laille E; Vaishampayan U; Chung V; Kelly K; Dowlati A; Alese OB; Harvey RD; Haluska P; Siu LL -
Pack-splitting to improve cost-effectiveness of oral agents in oncology.
Clin Adv Hematol Oncol Volume: 18 Page(s): 614 - 616
10/01/2020 Authors: Harvey RD -
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
J Immunother Cancer Volume: 8
10/01/2020 Authors: Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA -
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA -
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.
J Oncol Pharm Pract Volume: 26 Page(s): 1461 - 1474
09/01/2020 Authors: Harvey RD; Adams VR; Beardslee T; Medina P -
Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors
Volume: 80
08/01/2020 Authors: Mita M; Mita A; Hamilton E; Falchook GS; Postow M; Chmielowski B; Schilder RJ; Strauss J; Lim E; Pant S -
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey.
JCO Oncol Pract Volume: 16 Page(s): 417 - 421
07/01/2020 Authors: Waterhouse DM; Harvey RD; Hurley P; Levit LA; Kim ES; Klepin HD; Mileham KF; Nowakowski G; Schenkel C; Davis C -
Reply to Body fat indices and survival in immunotherapy-treated patients with cancer.
Cancer Volume: 126 Page(s): 3157 - 3159
07/01/2020 Authors: Martini DJ; Liu Y; Master VA; Harvey RD; Bilen MA -
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA -
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.
J Pharm Pract Volume: 33 Page(s): 338 - 349
06/01/2020 Authors: Medina P; Jeffers KD; Trinh VA; Harvey RD -
Effect of informational charts on patient understanding of nontherapeutic research procedures in phase I trials.
Volume: 38
05/20/2020 Authors: Campbell GP; Abernethy ER; Cook JW; Lohani M; Lewis CM; Switchenko JM; Dixon MD; Harvey D; Pentz RD -
In Reply.
Oncologist Volume: 25 Page(s): e876
05/01/2020 Authors: Bilen MA; Master VA; Harvey RD -
Precision Oncology Comes of Age: Tumor-Agnostic Approaches.
J Adv Pract Oncol Volume: 11 Page(s): 221 - 225
04/01/2020 Authors: Lewis C; Harvey RD -
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol Volume: 38 Page(s): 1081
04/01/2020 Authors: Markham MJ; Wachter K; Agarwal N; Bertagnolli MM; Chang SM; Dale W; Diefenbach CSM; Rodriguez-Galindo C; George DJ; Gilligan TD -
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
Oncologist Volume: 25 Page(s): e405 - e411
03/01/2020 Authors: Balogh EP; Bindman AB; Eckhardt SG; Halabi S; Harvey RD; Jaiyesimi I; Miksad R; Moses HL; Nass SJ; Schilsky RL -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Pharmacotherapy Volume: 40 Page(s): 133 - 141
02/01/2020 Authors: Hall KH; Liu Y; Jiang C; Harvey RD -
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer Volume: 126 Page(s): 575 - 582
02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT -
Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
Clin Transl Sci Volume: 13 Page(s): 41 - 46
01/01/2020 Authors: Vishwanathan K; Cantarini M; So K; Masson E; Fetterolf J; Ramalingam SS; Harvey RD -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
Oncologist
12/04/2019 Authors: Balogh EP; Bindman AB; Eckhardt SG; Halabi S; Harvey RD; Jaiyesimi I; Miksad R; Moses HL; Nass SJ; Schilsky RL -
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL -
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Cancer Chemother Pharmacol Volume: 84 Page(s): 1289 - 1301
12/01/2019 Authors: Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R -
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
JAMA Oncol Volume: 5 Page(s): 1691 - 1692
12/01/2019 Authors: Harvey RD; Ratain MJ -
Variation in Estimated Glomerular Filtration Rate Values Before Nephrectomy Based on Cystatin C, Chronic Kidney Disease Epidemiology Collaboration, Cockcroft-Gault, and Modification of Diet in Renal Disease Formulas
Volume: 229 Page(s): S323 - S323
10/01/2019 Authors: Hong G; Henry M; Pirani F; Patil D; Ogan K; Connor M; Bilen MA; Harvey RD; Bryksin J; Master V -
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL -
A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice.
Malar J Volume: 18 Page(s): 234
07/12/2019 Authors: Mimche SM; Lee C-M; Liu KH; Mimche PN; Harvey RD; Murphy TJ; Nyagode BA; Jones DP; Lamb TJ; Morgan ET -
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.
Cancer Volume: 125 Page(s): 2322 - 2324
07/01/2019 Authors: Harvey RD; Zhang C; Lonial S; Kaufman JL; Chen Z -
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Br J Clin Pharmacol Volume: 85 Page(s): 1464 - 1473
07/01/2019 Authors: Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD -
Impact of broadening clinical trial eligibility criteria for advanced non small cell lung cancer patients: Real-world analysis.
Volume: 37
06/20/2019 Authors: Harvey RD; Rubinstein WS; Ison G; Khozin S; Chen L; Miller RS; Jun M; Stepanski E; Hyde B; Uldrick TS -
Reply to Tumor-associated macrophages: "Good cop-bad cop".
Cancer Volume: 125 Page(s): 1942 - 1943
06/01/2019 Authors: Bilen MA; Kissick HT; Harvey RD -
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
J Pharmacol Exp Ther Volume: 369 Page(s): 291 - 299
05/01/2019 Authors: Grande E; Harvey RD; You B; Batlle JF; Galbraith H; Sarantopoulos J; Ramalingam SS; Mann H; So K; Johnson M -
Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial.
JMIR Res Protoc Volume: 8 Page(s): e12125
04/30/2019 Authors: Shteamer JW; Harvey RD; Spektor B; Curseen K; Egan K; Chen Z; Gillespie TW; Sniecinski RM; Singh V -
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
J Oncol Pharm Pract Volume: 25 Page(s): 613 - 622
04/01/2019 Authors: Moore DC; Arnall JR; Harvey RD -
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Clin Pharmacokinet Volume: 58 Page(s): 431 - 449
04/01/2019 Authors: Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K -
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
Am J Clin Oncol Volume: 42 Page(s): 331 - 336
04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D -
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Br J Clin Pharmacol Volume: 85 Page(s): 530 - 539
03/01/2019 Authors: Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM -
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs Volume: 37 Page(s): 87 - 97
02/01/2019 Authors: Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB -
Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
Volume: 7
02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W -
Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and Echoes.
J Oncol Pract Volume: 15 Page(s): 91 - 92
02/01/2019 Authors: Harvey RD -
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J Volume: 9 Page(s): 3
01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT -
Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.
Ther Adv Med Oncol Volume: 11 Page(s): 1758835918818335
01/01/2019 Authors: Cook JW; McGrath MK; Dixon MD; Switchenko JM; Harvey RD; Pentz RD -
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer Volume: 125 Page(s): 127 - 134
01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL -
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
Br J Clin Pharmacol Volume: 84 Page(s): 2877 - 2888
12/01/2018 Authors: Harvey RD; Aransay NR; Isambert N; Lee J-S; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K -
Accelerating anticancer drug development - opportunities and trade-offs.
Nat Rev Clin Oncol Volume: 15 Page(s): 777 - 786
12/01/2018 Authors: Nass SJ; Rothenberg ML; Pentz R; Hricak H; Abernethy A; Anderson K; Gee AW; Harvey RD; Piantadosi S; Bertagnolli MM -
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Cancer Volume: 124 Page(s): 4358 - 4365
11/15/2018 Authors: Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD -
Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
Volume: 102 Page(s): E27 - E27
11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D -
Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Volume: 29 Suppl 8 Page(s): viii42
10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC -
Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL -
Rationale, Opportunities, and Reality of Biosimilar Medications.
N Engl J Med Volume: 379 Page(s): 694 - 695
08/16/2018 Authors: Lyman GH; Zon R; Harvey RD -
Reply to S.D. Lucio.
J Clin Oncol Volume: 36 Page(s): 2127
07/10/2018 Authors: Lyman GH; Zon R; Harvey RD; Schilsky RL -
Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
Volume: 78
07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R -
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Br J Clin Pharmacol Volume: 84 Page(s): 1156 - 1169
06/01/2018 Authors: Vishwanathan K; Dickinson PA; So K; Thomas K; Chen Y-M; De Castro Carpeo J; Dingemans A-MC; Kim HR; Kim J-H; Krebs MG -
Rationale, Opportunities, and Reality of Biosimilar Medications.
N Engl J Med Volume: 378 Page(s): 2036 - 2044
05/24/2018 Authors: Lyman GH; Zon R; Harvey RD; Schilsky RL -
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Volume: 36
05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN -
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Volume: 36
05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK -
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
J Clin Oncol Volume: 36 Page(s): 1389 - 1395
05/10/2018 Authors: Szmulewitz RZ; Peer CJ; Ibraheem A; Martinez E; Kozloff MF; Carthon B; Harvey RD; Fishkin P; Yong WP; Chiong E -
American Society of Clinical Oncology Statement: Biosimilars in Oncology.
J Clin Oncol Volume: 36 Page(s): 1260 - 1265
04/20/2018 Authors: Lyman GH; Balaban E; Diaz M; Ferris A; Tsao A; Voest E; Zon R; Francisco M; Green S; Sherwood S -
Intranasal Ketamine and Its Potential Role in Cancer-Related Pain.
Pharmacotherapy Volume: 38 Page(s): 390 - 401
03/01/2018 Authors: Singh V; Gillespie TW; Harvey RD -
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
Oncology Volume: 95 Page(s): 138 - 146
01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS -
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
Br J Cancer Volume: 117 Page(s): 1592 - 1599
11/21/2017 Authors: Papadopoulos KP; El-Rayes BF; Tolcher AW; Patnaik A; Rasco DW; Harvey RD; LoRusso PM; Sachdev JC; Abbadessa G; Savage RE -
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.
J Clin Oncol Volume: 35 Page(s): 3753 - 3759
11/20/2017 Authors: Lichtman SM; Harvey RD; Damiette Smit M-A; Rahman A; Thompson MA; Roach N; Schenkel C; Bruinooge SS; Cortazar P; Walker D -
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Clin Pharmacokinet Volume: 56 Page(s): 1355 - 1368
11/01/2017 Authors: Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K -
Science of Biosimilars.
J Oncol Pract Volume: 13 Page(s): 17s - 23s
09/01/2017 Authors: Harvey RD -
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.
Clin Pharmacol Ther Volume: 102 Page(s): 313 - 320
08/01/2017 Authors: Wu B; Lewis LD; Harvey RD; Rasmussen E; Gamelin E; Sun Y-N; Friberg G; Koyner JL; Dowlati A; Maitland ML -
Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
Volume: 35
05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E -
Enrollment into molecular selection trials and impact on patient disposition.
Volume: 35
05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD -
A phase I study of LY3022855, a colony stimulating factor-1 receptor (CSF-1 R) inhibitor in patients (pts) with advanced solid tumors.
Volume: 35
05/20/2017 Authors: Dowlati A; Rugo HS; Harvey RD; Kudchadkar RR; Carvajal RD; Manji GA; Hamid O; Klempner SJ; Tang S; Yu D -
A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).
Volume: 35
02/20/2017 Authors: Szmulewitz RZ; Ibraheem AF; Peer CJ; Figg WD; Carthon BC; Kozloff M -
A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors
Volume: 12 Page(s): S1278 - S1278
01/01/2017 Authors: Gold P; Harvey RD; Spira A; Bazhenova L; Nemunaitis J; Baranda J; Gadgeel S -
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Target Oncol Volume: 11 Page(s): 807 - 814
12/01/2016 Authors: Mita MM; Nemunaitis J; Grilley-Olson J; El-Rayes B; Bekaii-Saab T; Harvey RD; Marshall J; Zhang X; Strout V -
Preventing and Managing Toxicities of High-Dose Methotrexate.
Oncologist Volume: 21 Page(s): 1471 - 1482
12/01/2016 Authors: Howard SC; McCormick J; Pui C-H; Buddington RK; Harvey RD -
Precision, accuracy, and resolution-Dose selection of oral anticancer agents.
Cancer Volume: 122 Page(s): 3424 - 3427
11/15/2016 Authors: Beardslee TJ; Harvey RD -
Global population pharmacokinetic (PK) analysis of ixazomib, an oral proteasome inhibitor, including data from the phase 3 TOURMALINE-MM1 study: an application of model based analysis to influence posology decisions in oncology drug development
Volume: 43 Page(s): S110 - S111
10/01/2016 Authors: Gupta N; Diderichsen PM; Hanley MJ; Berg D; Harvey RD; Venkatakrishnan K -
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Br J Haematol Volume: 174 Page(s): 748 - 759
09/01/2016 Authors: Gupta N; Hanley MJ; Harvey RD; Badros A; Lipe B; Kukreti V; Berdeja J; Yang H; Hui A-M; Qian M -
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events.
Pharmacotherapy Volume: 36 Page(s): 617 - 622
06/01/2016 Authors: Lawson J; Switchenko JM; McKibbin T; Donald Harvey R -
Calcium and Cancer: Of Evil Humors and Innocent Bystanders.
J Oncol Pract Volume: 12 Page(s): 433 - 434
05/01/2016 Authors: Harvey RD -
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Oncologist Volume: 21 Page(s): 402 - 403
04/01/2016 Authors: Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L -
Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer.
J Adv Pract Oncol Volume: 7 Page(s): 299 - 301
04/01/2016 Authors: Padda SK; Harvey RD -
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Clin Cancer Res Volume: 22 Page(s): 847 - 857
02/15/2016 Authors: Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM -
A PHASE I STUDY TO ASSESS FOOD EFFECT ON OPROZOMIB IN PATIENTS WITH ADVANCED MALIGNANCIES.
Volume: 99 Page(s): S98 - S99
02/01/2016 Authors: Harvey RD; Gore L; Wang D; Mita A; Sharma S; Nemunaitis J; Papadopoulos K; Pinchasik D; Ou Y; Demirhan E -
DRUG-DRUG INTERACTION (DDI) STUDY BETWEEN THE INVESTIGATIONAL NAE INHIBITOR PEVONEDISTAT (TAK-924) AND FLUCONAZOLE OR ITRACONAZOLE IN PATIENTS WITH ADVANCED SOLID TUMORS.
Volume: 99 Page(s): S97 - S97
02/01/2016 Authors: Faessel HM; Harvey RD; Lockhart AC; Bauer TM; Wang L; Sedarati F; Santillana S; Nemunaitis JJ -
A PHASE I STUDY OF OPROZOMIB TO ASSESS DRUG-DRUG INTERACTION WITH MIDAZOLAM IN PATIENTS WITH ADVANCED MALIGNANCIES.
Volume: 99 Page(s): S100 - S100
02/01/2016 Authors: Tsimberidou AM; Ou Y; Xu Y; Wang Z; Harvey RD; Mita A; Sharma S; Papadopoulos K; Wang D; Pinchasik D -
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Expert Rev Clin Pharmacol Volume: 9 Page(s): 35 - 48
01/01/2016 Authors: Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF -
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Clin Cancer Res Volume: 22 Page(s): 34 - 43
01/01/2016 Authors: Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z -
Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Volume: 126
12/03/2015 Authors: Harvey RD; Chen YJ; Lethen J; Mahue M -
Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Oncotarget Volume: 6 Page(s): 30773 - 30786
10/13/2015 Authors: Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC -
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Transfusion Volume: 55 Page(s): 2351 - 2357
10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C -
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.
Support Care Cancer Volume: 23 Page(s): 2789 - 2797
09/01/2015 Authors: Baz R; Lin HM; Hui A-M; Harvey RD; Colson K; Gallop K; Swinburn P; Laubach J; Berg D; Richardson P -
A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
Volume: 75
08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB -
Development and testing of a tool to assess patient preferences for phase I clinical trial participation.
Psychooncology Volume: 24 Page(s): 835 - 838
07/01/2015 Authors: Pentz RD; Hendershot KA; Wall L; White TE; Peterson SK; Thomas CB; McCormick J; Green MJ; Lewis C; Farmer ZL -
POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Volume: 100 Page(s): 507 - 508
06/01/2015 Authors: Matous J; Siegel D; Lonial S; Harvey RD; Kasserra C; Li Y; Chen M; Doerr T; Sternas L; Zaki M -
Novel immunotherapeutics and cytochrome P450.
PHARMACOTHERAPY Volume: 35 Page(s): E92 - E92
05/01/2015 Authors: Wheeler S; Harvey RD -
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD -
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
CANCER Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VORINOSTAT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH VARYING DEGREES OF HEPATIC FUNCTION.
Volume: 97 Page(s): S67 - S68
02/01/2015 Authors: Yang H; Ramalingam S; Kummar S; Harvey R; Ivy P; Beumer J -
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Cancer Volume: 120 Page(s): 3940 - 3951
12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J -
MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
Volume: 124
12/06/2014 Authors: Matous J; Siegel DS; Lonial S; Harvey RD; Kasserra C; Li Y; Chen M; Doerr T; Sternas L; Zaki MH -
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Volume: 124
12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW -
Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
Volume: 124
12/06/2014 Authors: Harvey RD; Cong Z; Werther W; Lethen JL; Lonial S -
The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
Volume: 124
12/06/2014 Authors: Divino V; Dekoven M; Wang W; Kleinrock M; Harvey RD; Wade RL; Kaura S -
Pre-medications for cetuximab induced infusion reactions - commentary.
Oral Oncol Volume: 50 Page(s): e71
12/01/2014 Authors: McKibbin T; Donald Harvey R; Saba NF -
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Clin Colorectal Cancer Volume: 13 Page(s): 219 - 225
12/01/2014 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR -
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.
Am J Transplant Volume: 14 Page(s): 2691 - 2703
12/01/2014 Authors: Singh K; Stempora L; Harvey RD; Kirk AD; Larsen CP; Blazar BR; Kean LS -
Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J -
Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.
Clin Pharmacol Ther Volume: 96 Page(s): 449 - 457
10/01/2014 Authors: Harvey RD; Morgan ET -
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 356 - 369
10/01/2014 Authors: Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS -
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Oncotarget Volume: 5 Page(s): 8136 - 8146
09/30/2014 Authors: Soliman HH; Jackson E; Neuger T; Dees EC; Harvey RD; Han H; Ismail-Khan R; Minton S; Vahanian NN; Link C -
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Volume: 124 Page(s): 1038 - 1046
08/14/2014 Authors: Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J -
Immunologic and clinical effects of targeting PD-1 in lung cancer.
Clin Pharmacol Ther Volume: 96 Page(s): 214 - 223
08/01/2014 Authors: Harvey RD -
Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
Haemophilia Volume: 20 Page(s): e344 - e346
07/01/2014 Authors: Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL -
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Blood Volume: 123 Page(s): 3269 - 3276
05/22/2014 Authors: Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun S-Y; Boise LH; Lonial S -
Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC)
Volume: 32
05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; Harvey D; El-Rayes BF; Flowers C -
Development of a patient preference assessment tool for cancer patients considering phase I research
Volume: 32
05/20/2014 Authors: Pentz RD; White TE; Dossul T; Hendershot KA; Dixon M; Salvador C; Switchenko JM; Harvey D -
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e59 - e63
04/01/2014 Authors: Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL -
Taxanes: vesicants, irritants, or just irritating?
Ther Adv Med Oncol Volume: 6 Page(s): 16 - 20
01/01/2014 Authors: Barbee MS; Owonikoko TK; Harvey RD -
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.
Clin Pharmacol Volume: 6 Page(s): 87 - 96
01/01/2014 Authors: Harvey RD -
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1638 - 1649
11/01/2013 Authors: Koura DT; Horan JT; Langston AA; Qayed M; Mehta A; Khoury HJ; Harvey RD; Suessmuth Y; Couture C; Carr J -
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Haematologica Volume: 98 Page(s): 1753 - 1761
11/01/2013 Authors: Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K -
A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON SMALL CELL LUNG CANCER
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S628 - S629
11/01/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Saba NF; Kono SA; Behera M; Lewis C; Chen Z; Pickens A -
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
ONKOLOGIE Volume: 36 Page(s): 39 - 40
10/01/2013 Authors: Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K -
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Ann Pharmacother Volume: 47 Page(s): 1136 - 1142
09/01/2013 Authors: Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS -
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S -
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Clin Cancer Res Volume: 19 Page(s): 3631 - 3639
07/01/2013 Authors: Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz H-J; Kummar S; Harvey RD; Hamilton AL -
ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
Volume: 98 Page(s): 598 - 598
06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A -
Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
Volume: 31
05/20/2013 Authors: Saba NF; Kono SA; Mendel JR; Hurwitz SJ; Owonikoko TK; Lewis CM; Harvey D; Rogerio JW; Chen Z; Wadsworth T -
Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review.
Volume: 31
05/20/2013 Authors: Harvey RD; McKibbin T; Behera M; Ramalingam SS -
Integrating patients' values into decisions to enroll in phase I trials: A feasibility study.
Volume: 31
05/20/2013 Authors: Hendershot KA; Dossul T; Wall L; Owonikoko TK; Harvey RD; Thomas CB; McCormick JB; Khuri FR; Pentz RD -
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
BRITISH JOURNAL OF HAEMATOLOGY Volume: 161 Page(s): 20 - 20
04/01/2013 Authors: Siegel DS; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K -
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 159 - 161
04/01/2013 Authors: Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD -
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer Volume: 108 Page(s): 762 - 765
03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A -
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
J Thorac Oncol Volume: 8 Page(s): 369 - 372
03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z -
Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
Volume: 19 Page(s): S191 - S191
02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M -
A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early CD4+T Cell Proliferation and is Associated with Low Rates of Severe Acute GVHD
Volume: 19 Page(s): S327 - S328
02/01/2013 Authors: Tiwari D; Horan J; Langston A; Qayed M; Carr J; Renfroe H; Couture C; Khoury HJ; Robertson J; Harvey D -
Tools to optimize the functionality of a leukemia clinical trial team.
Leuk Lymphoma Volume: 54 Page(s): 110 - 116
01/01/2013 Authors: Bethelmie-Bryan B; Lord K; Holloway S; Safavi F; Shepard M; Rogers S; Harvey RD; Rodger K; Waller EK; El-Rayes B -
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study
Volume: 120
11/16/2012 Authors: Shah JJ; Zonder JA; Cohen A; Bensinger W; Kaufman JL; Orlowski RZ; Harvey RD; Abidi MH; Thomas SK; Walker D -
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.
Cancer Volume: 118 Page(s): 4571 - 4578
09/15/2012 Authors: Pentz RD; White M; Harvey RD; Farmer ZL; Liu Y; Lewis C; Dashevskaya O; Owonikoko T; Khuri FR -
IMPACT OF MULTIPLE MYELOMA AND ITS TREATMENT ON QUALITY OF LIFE: DEVELOPMENT OF A CONCEPTUAL MODEL
Volume: 97 Page(s): 444 - 444
07/16/2012 Authors: Baz R; Lin H; Hui A-M; Harvey R; Colson K; Gallop K; Swinburn P; Breheny K; Acaster S; Berg D -
MLN4924, AN INVESTIGATIONAL NEDD8-ACTIVATING ENZYME (NAE) INHIBITOR, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY LYMPHOMA OR MULTIPLE MYELOMA (MM): PHASE 1 DOSE-ESCALATION STUDY OF TWICE-WEEKLY DOSING
Volume: 97 Page(s): 432 - 433
07/16/2012 Authors: Harvey R; Lebovic D; Lonial S; Jakubowiak A; Pickard M; McDonald A; Mulligan G; Blakemore S; Kuan S; Dezube B -
PLASMA CELL LEUKEMIA: SUSTAINED RESPONSES ARE POSSIBLE WITH INNOVATIVE TREATMENT STRATEGIES
Volume: 97 Page(s): 601 - 601
07/16/2012 Authors: Nooka A; Kaufman J; Muppidi S; Harvey R; Gleason C; Heffner L; Langston A; Casbourne D; Boise L; Lonial S -
CARFILZOMIB DOSE AND SCHEDULE NEED NOT BE ADJUSTED FOR BASELINE RENAL DYSFUNCTION, INCLUDING PATIENTS ON HEMODIALYSIS
Volume: 97 Page(s): 346 - 346
07/16/2012 Authors: Harvey D; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman J -
Using proton MRSI to predict response to vorinostat treatment in recurrent GBM.
Volume: 30
05/20/2012 Authors: Shim H; Voloschin AD; Wei L; Hwang SN; Miller AH; Guo Y; Brat D; Holder CA; Read WL; Kopcewicz K -
Physicians' ability to correctly identify values important to cancer patients enrolled in phase I clinical trials.
Volume: 30
05/20/2012 Authors: Pentz RD; Liu Y; Wall L; Daugherty C; Green MJ; Hlubocky FJ; Peterson SK; Sun CC; Dixon M; Harvey RD -
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF -
A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
Volume: 30
05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y -
An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Barbee MS; Wilson NM; Harvey RD; McKibbin T; Lonial S; Kaufman JL; Shah KS -
Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
Volume: 30
05/20/2012 Authors: Harvey RD; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman JL -
Research biopsies in phase I studies: views and perspectives of participants and investigators.
IRB Volume: 34 Page(s): 1 - 8
01/01/2012 Authors: Pentz RD; Harvey RD; White M; Farmer ZL; Dashevskaya O; Chen Z; Lewis C; Owonikoko TK; Khuri FR -
Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation.
Int J Cancer Volume: 129 Page(s): 2744 - 2755
12/01/2011 Authors: Thaiparambil JT; Bender L; Ganesh T; Kline E; Patel P; Liu Y; Tighiouart M; Vertino PM; Harvey RD; Garcia A -
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Volume: 118 Page(s): 1266 - 1266
11/18/2011 Authors: Lonial S; Cohen A; Zonder J; Benzinger WI; Kaufman JL; Orlowski RZ; Harvey RD; Alexanian R; Thomas SK; Weber D -
ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
Volume: 118 Page(s): 809 - 810
11/18/2011 Authors: Shah JJ; Zonder J; Cohen A; Orlowski RZ; Alexanian R; Thomas SK; Weber D; Kaufman JL; Harvey RD; Walker D -
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
BLOOD Volume: 118 Page(s): 1691 - 1691
11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S -
Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
Volume: 118 Page(s): 1287 - 1288
11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL -
Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis
Volume: 118 Page(s): 822 - 822
11/18/2011 Authors: Harvey RD; Jacobus SJ; Rajkumar SV; Greipp PR; Lonial S -
MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells
Volume: 118 Page(s): 815 - 816
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Cancer Volume: 117 Page(s): 4049 - 4059
09/01/2011 Authors: Kauh J; Chanel-Vos C; Escuin D; Fanucchi MP; Harvey RD; Saba N; Shin DM; Gal A; Pan L; Kutner M -
A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
Volume: 47 Page(s): S153 - S153
09/01/2011 Authors: Harvey RD; Lewis CM; Kauh JS; Owonikoko TK; Akintayo A; Karol M; Teofilovici F; Lufkin JM; Khuri FR; Ramalingam SS -
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
Transfusion Volume: 51 Page(s): 1779 - 1783
08/01/2011 Authors: Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR -
A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S967 - S968
06/01/2011 Authors: Owonikoko TK; Force S; Sica G; Bechara R; Harvey RD; Sun S-Y; Saba N; Rogerio J; Gal A; Kono S -
MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Kauh JS; Shapiro G; Cohen RB; Clark JW; Harvey RD; Cleary JM; Mahalingam D; Kuan S; McDonald A; Berger A -
Withaferin A inhibits breast cancer invasion and metastasis at subcytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Thaiparambil JT; Bender L; Ganesh T; Kline E; Patel P; Liu Y; Tighiouart M; Vertino PM; Harvey RD; Garcia A -
Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
Haemophilia Volume: 17 Page(s): 155 - 156
01/01/2011 Authors: Kempton CL; Meeks SL; Donald Harvey R; Abshire TC -
Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma
Volume: 116 Page(s): 1155 - 1155
11/19/2010 Authors: Shah JJ; Harvey RD; O'Connor OA; Jakubowiak AJ; Smith MR; Orlowski RZ; Mulligan GJ; Smith PG; Pickard MD; Dezube BJ -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
Volume: 116 Page(s): 1251 - 1251
11/19/2010 Authors: Kaufman JL; Shah JJ; Laubach JP; Heffner L; Francis D; Harvey RD; Lewis C; Tighiouart M; Richardson P; Orlowski RZ -
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD -
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
J Clin Oncol Volume: 28 Page(s): 4507 - 4512
10/10/2010 Authors: Ramalingam SS; Kummar S; Sarantopoulos J; Shibata S; LoRusso P; Yerk M; Holleran J; Lin Y; Beumer JH; Harvey RD -
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Cancer Volume: 116 Page(s): 3903 - 3909
08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ -
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
J Clin Oncol Volume: 28 Page(s): 3015 - 3022
06/20/2010 Authors: Tong W-G; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA -
MLN4924, A NOVEL NAE INHIBITOR IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL): PHASE 1 DOSE-ESCALATION STUDY
Volume: 95 Page(s): 160 - 160
06/15/2010 Authors: Shah J; Jakubowiak A; O'Connor O; Orlowski R; Patterson M; Harvey D; Berger A; McDonald A; Mulligan G; Boral A -
MLN4924, A NOVEL NAE INHIBITOR IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL): PHASE 1 DOSE-ESCALATION STUDY
Volume: 95 Page(s): 160 - 160
06/01/2010 Authors: Shah J; Jakubowiak A; O'Connor O; Orlowski R; Patterson M; Harvey D; Berger A; McDonald A; Mulligan G; Boral A -
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR -
Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Harvey RD; Kauh JS; Ramalingam SS; Lewis CM; Chen Z; Lonial S; Blount IC; Shin DM; Khuri FR; Owanikoko TK -
Myelodysplastic syndromes and the role of iron overload.
Am J Health Syst Pharm Volume: 67 Page(s): S3 - S9
04/01/2010 Authors: Harvey RD -
Iron overload in myelodysplastic syndromes. Introduction.
Am J Health Syst Pharm Volume: 67 Page(s): S2
04/01/2010 Authors: Harvey RD; Fausel CA -
Through the Looking Glass: The Evolution of Erythropoiesis-Stimulating Agent Use The Bennett/McKoy/Henke et al article reviewed
ONCOLOGY-NEW YORK Volume: 24 Page(s): 269 - 274
03/01/2010 Authors: Harvey RD; Khuri FR; Kauh JS -
Through the looking glass: the evolution of erythropoiesis-stimulating agent use.
Oncology (Williston Park) Volume: 24 Page(s): 269 - 274
03/01/2010 Authors: Harvey RD; Khuri FR; Kauh JS -
Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology.
Volume: 67 Page(s): S3 - S9
01/01/2010 Authors: Adams VR; Harvey RD -
Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma
Volume: 114 Page(s): 1492 - 1493
11/20/2009 Authors: Lonial S; Harvey RD; Francis D; Gul E; Jagannath S; Farag S; Hoth D; Frumento R; Garlich JR; Trudel S -
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
Volume: 114 Page(s): 1481 - 1481
11/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard AM; Aceo F; Gul E; Kakar S; Krishnan AY; Reece DE -
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
Leukemia Volume: 23 Page(s): 1939 - 1940
11/01/2009 Authors: Harvey RD; Nettles J; Wang B; Sun S-Y; Lonial S -
A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S594 - S595
09/01/2009 Authors: Owonikoko TK; Ramalingam SS; Harvey D; Saba NF; Kauh J; Shin DM; Sun S-Y; Browning K; Tighiouart M; Khuri FR -
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
Volume: 27
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS -
Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin
Volume: 27
05/20/2009 Authors: Kauh JS; Cohen R; Clarke JW; Harvey R; Mulligan G; Venkatakrishnan K; Berger A; Smith PG; Petruzelli L; Sarantopoulos J -
A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.
J Clin Oncol Volume: 27 Page(s): 8597
05/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard A; Harvey D; Kaufman J -
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial.
J Clin Oncol Volume: 27 Page(s): 2512
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD -
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
J Clin Oncol Volume: 27 Page(s): 8060
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS -
Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin.
J Clin Oncol Volume: 27 Page(s): 2562
05/20/2009 Authors: Kauh JS; Cohen R; Clarke JW; Harvey R; Mulligan G; Venkatakrishnan K; Berger A; Smith PG; Petruzelli L; Sarantopoulos J -
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial
Volume: 27
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD -
Using Proton MRS to predict responses of SAHA treatment in glioblastoma
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Yoon Y; Wei L; Zhang Z; Harvey RD; Park J; Olson J; Hu X; Shim H -
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Volume: 15 Page(s): 154 - 155
02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ -
A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
Volume: 112 Page(s): 1270 - 1270
11/16/2008 Authors: Lonial S; Francis D; Karanes C; Trudel S; Reece DE; Krishnan A; Buacharem M; Smith R; Zaman F; Gul E -
A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor in Chronic Lymphocytic Leukemia and Multiple Myeloma.
Volume: 112 Page(s): 1090 - 1090
11/16/2008 Authors: Wierda WG; Chen R; Plunkett W; Coutre S; Badros AZ; Popplewell L; Siegel D; Sinha R; Harvey D; Fox J -
Defining the interaction of docetaxel and lonafarnib in patients with advanced malignancies
Volume: 68
05/01/2008 Authors: Kauh J; Fanucchi M; Escuin D; Saba N; Shin D; Gal A; Kutner M; Harvey D; Giannakakou P; Khuri F -
The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma
Page(s): 309 - 322
01/01/2008 Authors: Harvey RD; Silberman J; Lonial S -
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Future Oncol Volume: 3 Page(s): 639 - 647
12/01/2007 Authors: Harvey RD; Lonial S -
Novel therapeutic agents in the management of hemorrhage and thrombosis.
Cardiovasc Hematol Agents Med Chem Volume: 4 Page(s): 319 - 334
10/01/2006 Authors: Kempton CL; Harvey RD; Roberts HR -
Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG).
Biol Blood Marrow Transplant Volume: 12 Page(s): 786 - 788
07/01/2006 Authors: Coghill J; Comeau T; Shea T; Braddy L; Bandarenko N; Afenyi-Annan A; Harvey D -
A cautionary tale: Fatal outcome of methotrexate therapy given for management of ectopic pregnancy (vol 107, pg 439, 2006)
OBSTETRICS AND GYNECOLOGY Volume: 107 Page(s): 1171 - 1171
05/01/2006 Authors: Kelly H; Harvey D; Moll S -
A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy.
Obstet Gynecol Volume: 107 Page(s): 439 - 441
02/01/2006 Authors: Kelly H; Harvey D; Moll S -
Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Biol Blood Marrow Transplant Volume: 11 Page(s): 1022 - 1030
12/01/2005 Authors: Gabriel DA; Shea TC; Serody JS; Moore DT; Kirby SL; Harvey D; Krasnov C -
Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction.
Pharmacotherapy Volume: 25 Page(s): 71S - 72S
11/01/2005 Authors: Harvey RD -
The patient: Emerging clinical applications of intravenous immunoglobulin.
Volume: 25 Page(s): 85S - 93S
11/01/2005 Authors: Harvey RD -
Acute hemolysis associated with passively acquired anti-A from intravenous gamma globulin (IVIG)
Volume: 45 Page(s): 134A - 134A
09/01/2005 Authors: Braddy L; Coghill J; Afenyi-Annan A; Harvey D; Shea T; Comeau T; Bandarenko N -
Intravenous busulfan test dose clearance comparison with first and thirteenth dose systemic exposure in allogenic bone marrow transplantation patients.
Volume: 23 Page(s): 599S - 599S
06/01/2005 Authors: Harvey RD; Shea T; Walko C; Krasnow C; Patel L; Serody J; Gabriel D; Comeau T; Lindley C -
90 hour continuous intravenous busulfan infusion: PK and test dose predictability in allogenic bone marrow transplantation patients.
Volume: 23 Page(s): 598S - 598S
06/01/2005 Authors: Walko CM; Lindley CM; Collins J; Krasnov C; Harvey RD; Gabriel DA; Serody J; Comeau T; Shea TC -
High relapse rate following alemtuzamab use in allogeneic transplants for myeloid hematologic malignancies
Volume: 11 Page(s): 28 - 29
02/01/2005 Authors: Shea TC; Serody J; Gabriel D; Comeauu T; Morris D; Irons R; Harvey D; Sharf A; Krasnov C; Dunphy C -
High relapse rate following alemtuzamab use in allogeneic transplants for myeloid hematologic malignancies.
Volume: 104 Page(s): 506A - 506A
11/16/2004 Authors: Shea TC; Serody J; Gabriel D; Comeau T; Harvey D; Irons R; Morris D; Sharf A; Krasnov C; Dunphy C -
BK virturia in patients undergoing allogeneic hematopoietic stem cell transplantation: Increased incidence in patients receiving alemtuzumab (ALEM) as conditioning therapy and lack of efficacy of cidofovir
Volume: 104 Page(s): 864A - 864A
11/16/2004 Authors: Comeau T; Shea T; Gabriel D; Morris D; Irons R; Harvey D; Sharf A; Krasnov C; Dunphy C; Benderenko N -
Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Anticancer Drugs Volume: 15 Page(s): 453 - 459
06/01/2004 Authors: Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S -
Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy
ANTI-CANCER DRUGS Volume: 15 Page(s): 453 - 459
06/01/2004 Authors: Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WR; Garbriel D; Serody J; Kirby S -
Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
Support Care Cancer Volume: 11 Page(s): 516 - 521
08/01/2003 Authors: Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C -
Use of prophylactic ganciclovir (G) and CMV antigen (Ag) screening in allogeneic transplant patients (pts) receiving high-dose steroids (HDS).
Volume: 100 Page(s): 442B - 442B
11/16/2002 Authors: Engelhardt B; Serody J; Gabriel D; Kirby S; Wily J; Bigelow S; Harvey D; Moore D; Gilligan P; Banderenko N -
Brain metastases.
Curr Treat Options Oncol Volume: 2 Page(s): 537 - 547
12/01/2001 Authors: Ewend MG; Carey LA; Morris DE; Harvey RD; Hensing TA -
Dose response of recombinant factor VIIa in patients with hemophilia and liver disease.
Volume: 98 Page(s): 70B - 70B
11/16/2001 Authors: Escobar M; Melton LG; Thompson CM; Gabriel DA -
Experience with the use of recombinant factor VIIa in a university hospital.
BLOOD Volume: 98 Page(s): 70B - 70B
11/16/2001 Authors: Escobar M; Harvey RD -
Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
Bone Marrow Transplant Volume: 28 Page(s): 405 - 407
08/01/2001 Authors: Blatt J; Gold SH; Wiley JM; Monahan PE; Cooper HC; Harvey D -
Granulocyte colony-stimulating factor use in cancer patients.
Ann Pharmacother Volume: 34 Page(s): 851 - 857
01/01/2000 Authors: Baker J; McCune JS; Harvey RD; Bonsignore C; Lindley CM -
Serotonin antagonists. An update.
Cancer Pract Volume: 6 Page(s): 133 - 135
01/01/1998 Authors: Harvey RD; Lindley CL